ClinicalTrials.gg
Active, not recruitingNCT06213324Updated Nov 4, 2026

Neural Circuit Effects of Ketamine in Depression

A Phase 4 interventional study of Ketamine and Placebo in Major Depressive Disorder, sponsored by Icahn School of Medicine at Mount Sinai. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Icahn School of Medicine at Mount Sinai · Phase 4, Interventional, and Basic science

How we know

Updated Nov 4, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies testing ketamine in Depressive Disorder, Major — 21 open to participants now, 26 under way, 5 of them phase 3. Ketamine · Depressive Disorder, Major.

Enrollment
12th of 89
120 · median 38
Started
2024
with 7 others
Phase 4
16 of 89
2 open now
Primary completion
2028-01
later than 17 of 25 live
Registered
76th of 89
by date

Among the 89 studies testing ketamine in Depressive Disorder, Major, this one is the 12th largest by enrollment, is one of 8 that started in 2024, is one of 16 in phase 4, reaches primary completion later than 17 of the 25 other live ones, and was the 76th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

21 of the 89 studies testing ketamine in Depressive Disorder, Major are open now, in 9 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About ketamine

Ketamine: first FDA approval 1970 (KETALAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies testing ketamine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

MDD Group

  • Male or female aged 18-65 years;
  • Ability for participant to comply with the requirements of the study as determined by the PI;
  • Capacity to provide ;
  • Meets diagnostic criteria for current MDD according to the -Fifth Edition (DSM-5);
  • In a current major depressive episode (MDE) of at least moderate severity according to DSM-5;
  • Women must be using a medically accepted reliable means of (if using an oral contraceptive medication, they must also be using a barrier contraceptive) or not be of (i.e., surgically sterile, for at least one year).
  • Women of childbearing potential must have a negative pregnancy test at screening and prior to the infusion.

HC Group

  • Male or female aged 18-65 years;
  • Capacity to provide informed consent;
  • Women must be using a medically accepted reliable means of contraception (if using an oral contraceptive medication, they must also be using a barrier contraceptive) or not be of childbearing potential (i.e., surgically sterile, postmenopausal for at least one year).
  • Ability for participant to comply with the requirements of the study as determined by the PI;

Exclusion criteria

Exclusion Criteria:

MDD Group

  • Current or history of schizophrenia or other psychotic disorder/episode, bipolar disorder, neurodevelopmental disorder, or neurocognitive disorder;
  • Current major depressive disorder with psychotic features;
  • Substance use disorder within the past 2 years*;
  • Lifetime history of ketamine use disorder;
  • Antidepressant medication within 2 weeks of Baseline (4 weeks for fluoxetine);
  • Severe current illness as reflected by a CGI score >5;
  • Any unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease); endocrinologic, neurologic (including history of severe head injury), immunologic, or hematologic disease;
  • abnormalities of laboratories, physical examination, or ;
  • Positive urine toxicology screen for drugs of abuse at the time of screening, except cannabis;
  • Women who plan to become pregnant, are pregnant or are breast-feeding (because the medical risk of using ketamine during pregnancy and breast-feeding is unknown);
  • Active suicidal intent or plan; CSSRS score >2;
  • Any to MRI, including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more;
  • Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.

HC Group

  • Current or history of any psychiatric, neurodevelopmental disorder, or neurocognitive disorder;
  • Substance use disorder within the past 2 years*;
  • Any unstable medical illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease); endocrinologic, neurologic (including history of severe head injury), immunologic, or hematologic disease;
  • Clinically significant abnormalities of laboratories or physical examination;
  • Positive urine toxicology screen for drugs of abuse at the time of screening, except cannabis;
  • Current pregnancy;
  • Women who are breast feeding;
  • Active suicidal intent or plan; CSSRS score >2;
  • Any contraindications to MRI, including claustrophobia, any trauma or surgery which may have left magnetic material in the body, magnetic implants or pacemakers, and inability to lie still for 1 hour or more.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    Ketamine

    Participants in the ketamine arm will receive a single infusion of ketamine

    Drug: Ketamine

  • Placebo comparator
    Placebo

    Participants in the placebo arm will receive a single placebo infusion of normal saline

    Drug: Placebo

Interventions

  • 0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously

  • DrugPlacebo

    Normal saline delivered intravenously

06

What researchers measure

Primary outcomes

  1. sgACC response to the Incentive Flanker Task

    Subgenual anterior cingulate cortex (sgACC) response to reward measured by the BOLD (Blood Oxygen Level Dependent) signal within the sgACC region of the brain, during an fMRI Incentive Flanker Task in healthy controls and in adults with MDD. BOLD signal is the unit of measure of this outcome.

    Time frame: Baseline

Secondary outcomes

  1. Treatment-related change in sgACC response to the Incentive Flanker Task

    Treatment-related change from baseline to 1-day post treatment in subgenual anterior cingulate cortex (sgACC) response to reward measured by the BOLD (Blood Oxygen Level Dependent) signal within the sgACC region of the brain, during an fMRI Incentive Flanker Task. MDD adults only.

    Time frame: Baseline and Day 1

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol

Time frame: Immediately following publication. No end date.

Access criteria: Investigators whose proposed use of the data has been approved by an independent review committee ('learned intermediary') identified for this purpose. Any purpose. Specify Other Mechanism Data from this study will be submitted to the National Institute of Mental Health Data Archive (NDA). The NDA is a data repository run by the National Institute of Mental Health (NIMH) that facilitates data sharing across mental health and other research communities. Periodically during and after study completion, the researchers will upload deidentified data information to the NDA. Other researchers nationwide can then file an application to obtain access to deidentified study data for research purposes.

Data sharing details ↗ · nda.nih.gov

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2028, 47 months after the start.

Of 79 non-industry phase 4 interventional studies under Depressive Disorder, Major, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 47 months is close to that.

Counting every sponsor, half of 98 studies reached it within 35 months; a quarter within 20 and three quarters within 58.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Mar 2028 → Jan 2028 and completion Apr 2028 → Feb 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 9, 2024
First posted
Jan 19, 2024
StartActual
Jan 31, 2024
Primary completionEst.
Jan 1, 2028was Mar 2028
CompletionEst.
Feb 1, 2028was Apr 2028
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 4, 2026
Primary completion
Mar 30, 2028→Jan 1, 2028
Nov 4, 2026
Study completion
Apr 30, 2028→Feb 1, 2028
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Active, not recruiting
    Primary completion Mar 30, 2028→Jan 1, 2028
    Study completion Apr 30, 2028→Feb 1, 2028
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06213324
Responsible party
James Murrough (Professor of Psychiatry and Neuroscience, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Jan 19, 2024
Start date
Jan 31, 2024
Primary completion
Jan 1, 2028 (estimated)
Completion
Feb 1, 2028 (estimated)
Last update
Nov 4, 2026

Study contacts

James Murrough, MD/PhD
principal investigator · Icahn School of Medicine at Mount Sinai
Laurel Morris
principal investigator · Icahn School of Medicine at Mount Sinai

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketamine

Start the discussion